Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Argument For Metastatic Endpoints

Executive Summary

NIH official has published articles urging drug development focused on metastasis-prevention.

You may also be interested in...



PhRMA’s Vision For 21st Century Marketing Would Reshape Supplemental NDAs

Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.

Disparity In Breast Cancer Population Is Challenge For FDA: Can Genetic Testing Help?

Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.

Breast Cancer Patients, FDA Disagree On Value Of Time-To-Metastasis Endpoints

FDA doesn’t seem ready to support clinical trial endpoint asked for by metastatic breast cancer patients at patient-focused drug development meeting.

Topics

UsernamePublicRestriction

Register

PS056774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel